Nyxoah (NASDAQ:NYXH) Given New $15.00 Price Target at HC Wainwright

Nyxoah (NASDAQ:NYXH) had its target price reduced by HC Wainwright from $17.00 to $15.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Nyxoah’s Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.

Separately, Stifel Nicolaus lowered their target price on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, March 14th.

Nyxoah Price Performance

NYXH stock opened at $7.65 on Wednesday. The stock has a market capitalization of $260.56 million, a price-to-earnings ratio of -4.09 and a beta of 1.42. The stock’s fifty day simple moving average is $10.35 and its 200-day simple moving average is $9.34. Nyxoah has a 52-week low of $6.76 and a 52-week high of $13.50. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The company had revenue of $1.35 million during the quarter, compared to analyst estimates of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. Equities research analysts expect that Nyxoah will post -1.91 EPS for the current year.

Institutional Investors Weigh In On Nyxoah

A number of institutional investors and hedge funds have recently bought and sold shares of NYXH. Vestal Point Capital LP acquired a new position in Nyxoah in the fourth quarter worth approximately $23,394,000. Ameriprise Financial Inc. purchased a new position in Nyxoah in the 4th quarter worth about $135,000. Walleye Capital LLC lifted its stake in Nyxoah by 23.9% during the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after buying an additional 2,862 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Nyxoah in the fourth quarter worth about $187,000. Finally, Geode Capital Management LLC increased its position in shares of Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after acquiring an additional 2,774 shares in the last quarter.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.